Inicio / Hematología / Abstracts de hematología / PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

0 / 5 (0 votos)
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

The Lancet Haematology

Fecha de publicación:

DOI: https://doi.org/10.1016/S2352-3026(21)00101-0

Autores: Stefanie Kreissl, MD, Helen Goergen, Dipl-Math, Ina Buehnen, MA, Prof Carsten Kobe, MD, Alden Moccia, MD, Prof Richard Greil, MD, Dennis A Eichenauer, MD, Josée M Zijlstra, MD, Jana Markova, MD, Julia Meissner, MD, Prof Michaela Feuring-Buske, MD, Martin Soekler, MD, Prof Hans-Joachim Beck, MD, Wolfgang Willenbacher, MD, Prof Wolf-Dieter Ludwig, MD, Prof Thomas Pabst, MD, Prof Max S Topp, MD, Felicitas Hitz, MD, Prof Martin Bentz, MD, Prof Ulrich Bernd Keller, MD, Dagmar Kühnhardt, MD, Prof Helmut Ostermann, MD, Prof Bernd Hertenstein, MD, Prof Walter Aulitzky, MD, Prof Georg Maschmeyer, MD, Tom Vieler, MD, Prof Hans Eich, MD, Christian Baues, MD, Prof Harald Stein, MD, Michael Fuchs, MD, Prof Volker Diehl, MD, Prof Markus Dietlein, MD, Prof Andreas Engert, MD, Prof Peter Borchmann, MD 

Background: The German Hodgkin Study Group’s HD18 trial established the safety and efficacy of PET-guided eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) for the treatment of advanced-stage Hodgkin lymphoma. However, because of a protocol amendment during the enrolment period (June 1, 2011) that changed standard treatment from eight to six cycles, the results of the HD18 trial have been partially immature. We report a prespecified 5-year follow-up analysis of the completed HD18 trial.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.